Elite Health Systems Inc.

For the period ended Dec 31, 2024. Filed Apr 2, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Apr 2, 2025

EHSIStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 15. Exhibits, Financial Statement Schedules

(a) (1)Financial Statements and Financial Statement Schedules. The following are filed as part of this report:

	Page No.
Consolidated Financial Statements of the Company	F-1
Reports of Independent Registered Public Accounting Firm	F-2
Consolidated Balance Sheets as of December 31, 2024, and 2023	F-4
Consolidated Statements of Operations for the years ended December 31, 2024, and 2023	F-5
Consolidated Statements of Stockholders' Equity for the years ended December 31, 2024, and 2023	F-6
Consolidated Statements of Cash Flows for the years ended December 31, 2024, and 2023	F-7
Notes to Consolidated Financial Statements	F-8

(2) Financial Statement Schedules. All financial statement schedules as required by Item 8 and Item 15 of Form 10-K have been omitted because the information requested is not required, not applicable, or is shown in the Consolidated Financial Statements or Notes thereto.

(b)Exhibits:

21.1*	List of Subsidiaries
2.1	Agreement and Plan of Reorganization, dated as of September 3, 2015, among U.S. Neurosurgical, Inc. (“USN”), U.S. Neurosurgical Holdings, Inc., (“Holdings”), and U.S. Neurosurgical Merger Sub, Inc. (incorporated herein by reference to Exhibit 2.1 to our Form 8-K as filed September 3, 2015)
2.2	Share Exchange Agreement and Plan of Reorganization, dated as of October 1, 2021, between U.S. NeuroSurgical, Inc., Elite Health Plan, Inc. and all of the shareholders of Elite Health Plan, Inc. (incorporated herein by reference to Exhibit 2.1 to our Form 8-K Current Report as filed October 6, 2021)
2.3	Share Exchange Agreement, dated as of November 27, 2023, between Holdings and certain shareholders of USN. (incorporated herein by reference to Exhibit 2.1 to our Form 8-K Current Report as filed November 27, 2023)
3.1	Form of Amended and Restated Certificate of Incorporation of U.S. NeuroSurgical Holdings, Inc. (“Holdings”) (incorporated herein by reference to Exhibit 3.1 to our Form 8-K as filed September 3, 2015)
3.2	Form of Amended and Restated Bylaws of Holdings (incorporated herein by reference to Exhibit 3.2 to our Form 8-K as filed September 3, 2015)
4.1	Form of Stock Certificate of Common Stock (incorporated herein by reference to Exhibit 4.1 to our Form 10 Registration Statement as filed July 1, 1999)
31.1*	Certifications of CEO and CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*	Certifications of CEO and CFO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS	Inline XBRL Instance Document
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase
101.LAB	Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	The Cover Page Interactive Data File, formatted in Inline XBRL (included within the Exhibit 101 attachments)

Filed herewith

(c)	Financial Statement Schedules. None

SIGNATURES

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Elite Health Systems Inc.
(Registrant)
By	/s/ Dr. Prasad Jeereddi
	Dr. Prasad Jeereddi
	CEO & Chairman of the Board
	and
	Principal Financial Officer
Dated:	April 2, 2025

In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

April 2, 2025	/s/ Dr. Prasad Jeereddi
	Dr. Prasad Jeereddi
	CEO & Chairman of the Board
April 2, 2025	/s/ Alan Gold
	Alan Gold
	Director
April 2, 2025	/s/ William F. Leimkuhler
	William F. Leimkuhler
	Director
April 2, 2025	/s/ William St. Lawrence
	William St. Lawrence
	Director

Contents

	Page
Consolidated Financial Statements	F-1
Reports of Independent Registered Public Accounting Firm (PCAOB ID 3233)	F-2
Consolidated Balance Sheets as of December 31, 2024, and 2023	F-3
Consolidated Statements of Operations for the years ended December 31, 2024, and 2023	F-4
Consolidated Statements of Stockholders' Equity for the years ended December 31, 2024, and 2023	F-5
Consolidated Statements of Cash Flows for the years ended December 31, 2024, and 2023	F-6
Notes to Consolidated Financial Statements	F-7

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.